Organ preservation in rectal cancer - Challenges and future strategies.
Neoadjuvant radiochemotherapy with subsequent total mesorectal excision is the standard of care for locally advanced rectal cancer. While this multimodal strategy has decreased local recurrences rates below 5%, long-term morbidities are considerable in terms of urinary, sexual or bowel functioning. At the same time approximately 10-20% of patients have no evidence of residual tumour in their surgical specimen. Pioneering studies from Brazil have suggested that surgery can safely be omitted in carefully selected patients with a clinical complete response after radiochemotherapy. Although confirmatory studies showed similar results, challenges in terms of optimizing radiochemotherapy for organ-preservation, appropriate selection of patients for non-operative management and the safety of this approach remain. The present review will summarize the current data on organ-preservation in rectal cancer and discuss the challenges that need to be addressed in future trials.
['Gani|C|C|', 'Bonomo|P|P|', 'Zwirner|K|K|', 'Schroeder|C|C|', 'Menegakis|A|A|', 'Rödel|C|C|', 'Zips|D|D|']
Organ preservation Rectal cancer Radiochemotherapy Chemoradiotherapy Radiotherapy Wait and see